



NEWS RELEASE

Savara Announces Participation in the Leerink Global Healthcare Conference

2025-03-03

LANGHORNE, Pa.--(BUSINESS WIRE)--Mar. 3, 2025-- **Savara Inc.** (Nasdaq: **SVRA**) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT.

The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website at <https://savarapharma.com/investors/events-presentations/> and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow[®] Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and [LinkedIn](#).

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250303602288/en/): <https://www.businesswire.com/news/home/20250303602288/en/>



Media and Investor Relations Contact

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

ir@savarapharma.com

Source: Savara Inc.